To systematically review the prognostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) for interim response assessment of patients with untreated advanced-stage Hodgkin's lymphoma (HL) or diffuse large B-cell lymphoma (DLBCL).
INTRODUCTION
Malignant lymphoma is the fifth most commonly diagnosed cancer in the United States. 1 With advances in treatments, Hodgkin's lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) are potentially curable lymphomas.
2, 3 However, challenges remain especially in the treatment for highrisk patients, 4 ,5 since more than half of these patients do not achieve long-term survival with currently available standard first-line chemotherapy. A possible treatment involves intensive and toxic polychemotherapy for advanced-stage HL 6 or firstline high-dose chemotherapy with stem-cell support for DLBCL, 7 depending on individual risk of treatment failure. Therefore, better identification of poor responders to first-line therapy is important to advance risk-adapted treatment strategies. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is a functional imaging test that has become widely used in the management of both HL and non-Hodgkin's lymphoma (NHL). 8 Studies that assessed FDG-PET as a prognostic tool performed during chemotherapy have reported the ability to predict poor outcomes. 8 However, the studies used different design, conduct, and reporting, making interpretation of the results difficult. In particular, inclusion of heterogeneous populations with different categories of disease (eg, limited-stage v advanced-stage HL or DLBCL v other aggressive NHLs) clearly affects the clinical applicability of the study results because each category has different clinical profiles (eg, treatment strategies, response, and prognosis). In this systematic review, we assessed the prognostic accuracy of FDG-PET performed during first-line therapy to predict disease progression or relapse in patients with advanced-stage HL and DLBCL, paying particular attention to the clinical applicability of the reported results.
METHODS

Data Sources and Searches
We searched Ovid MEDLINE and EMBASE from 1966 through July 2006, 9 and PubMed from August 2006 through July 2007 without language restriction. The search strategy can be found in online-only Appendix Table  A1 . This search was augmented by searches of SCOPUS and Biologic Abstracts. We also examined the reference lists of eligible studies, review articles, and textbooks.
Study Selection
Two reviewers (T.T., H.N.) screened abstracts and determined eligibility. Full-text articles were reviewed when abstracts did not provide sufficient information for determination. We included studies that evaluated FDG-PET performed between the first and the fourth cycle of first-line chemotherapy for patients with advanced-stage HL or DLBCL. We included both prospective and retrospective studies, and we considered clinical follow-up with or without pathologic confirmation to be a reference standard. We included studies that evaluated at least 10 patients and included at least five patients who progressed during chemotherapy or relapsed through clinical follow-up. We accepted studies in which patients received high-dose chemotherapy followed by autologous stem cell transplantation as long as it was administered as a part of primary therapy or consolidation therapy after standard induction chemotherapy. We excluded abstracts, editorials, comments, letters, and review articles. We excluded studies that enrolled patients with HIVassociated or post-transplant lymphoproliferative disorders.
Many studies did not meet all the inclusion criteria, but did partially include a relevant patient population. For these studies, we contacted the authors for relevant individual patient or subgroup data. When there was no response after 4 weeks, another correspondence was sent. When there was no response after the third communication attempt, we considered the request rejected.
Data Extraction and Quality Assessment
Two independent, board-certified hematologists (T.T., H.N.) abstracted relevant data. We extracted patients' demographic and clinical characteristics including the International Prognostic Scores (IPS) for advanced-stage HL 4 or the International Prognostic Indexes (IPI) for DLBCL, 5 therapeutic interventions, interim PET results, and final clinical outcomes. We subdivided the treatment failures into three categories based on the relative timing to the completion of first-line therapy: during therapy, after 1 year from diagnosis or the start of therapy, and in between. When the timing of completion of first-line therapy was unclear, we arbitrarily considered the treatment period to be 6 months. We also extracted the number of cases in remission but censored from follow-up within 1 year from the start of therapy (early censoring). One nuclear medicine specialist (T.N.) evaluated the technical specification and quality of PET procedures using recommended guidelines.
10
Reviewers were not blinded to the name of the journal. Inconsistencies between reviewers were either clarified by the authors or resolved by consensus.
To evaluate the quality, applicability, and reporting of the studies, we used QUADAS, a recently proposed tool to assess the quality of studies of diagnostic accuracy included in a systematic review.
11 Details on how we scored each item can be found in online-only Appendix Table A2 . We assessed only published data and did not use unpublished data because the latter was not available from all the studies.
Data Synthesis and Statistical Analysis
For each study, we constructed a 2 ϫ 2 contingency table consisting of true positive (TP), false positive (FP), false negative (FN), and true negative (TN), where all patients were categorized according to whether they were PET positive or negative, and whether they experienced treatment failure. In the main analysis, we employed the entire clinical follow-up as the reference standard. In sensitivity analysis, we categorized patients using shorter clinical follow-up as the alternative reference standard to focus on very early treatment failures (only during therapy or Ͻ 6 months), or early treatment failures (Ͻ 12 months). We counted patients in remission during the specified follow-up period as no treatment failure even if they eventually experienced treatment failure thereafter. We counted early censorings as no treatment failure in the main analysis. In sensitivity analysis to explore a worst-case scenario, early censorings were excluded from the analysis, and then counted as FP if they had negative PET results and were lost to follow-up early without treatment [12] [13] [14] We considered this category negative scan in the main analysis because this was how investigators analyzed the results. In sensitivity analyses, MRU results were excluded from analysis, considered positive, considered positive in the case of treatment failure and negative in the case of continuing remission (best-case scenario), and considered negative in the case of treatment failure and positive in the case of continuing remission (worstcase scenario).
We calculated sensitivity, specificity, and likelihood ratios (LRs) for each study. For the estimation of 95% CI, we used the binominal Wilson method for sensitivity and specificity, and normal approximation for LRs. Then we combined summary statistics, 95% confidence regions of summary sensitivity and specificity, and summary receiver operating characteristic (ROC) curves by the hierarchical SROC method, 15 which takes into account both withinstudy and between-studies variation. We fitted the model by using maximum likelihood estimation implemented in the GLLAMM algorithm 16 in STATA (version 9.2; Stata Corp, College Station, TX), and depicted the summary ROC curves and confidence regions for summary sensitivity and specificity. 17 We estimated the Q* statistic, 15 the point on the curve where sensitivity equals specificity, as global measures for the summary ROC.
To explore heterogeneity, we performed subgroup analyses by visual assessment of ROC plots and univariate meta-regression analyses. In the meta-regression, we incorporated study design or clinical characteristics as covariates into the bivariate model using Meta-Analyst (Tufts Medical Center, Boston, MA). Our preplanned analyses included characteristics of study design (prospective v retrospective), whether studies included more than 10 patients with treatment failure, rates of treatment failure, adoption of combined FDG-PET and computed tomography (FDG-PET/CT), the mean number of chemotherapy cycles before PET, timing of PET scan after the administration of chemotherapy, percentage of high or high-intermediate risk for DLBCL, and percentage of rituximab (R) use for DLBCL. We also performed posthoc analyses on the use of high-dose chemotherapy. Two-sided P values lower than .05 were considered to be statistically significant.
RESULTS
Search Results
Online-only Appendix Figure A1 summarizes the search results. We retrieved 23 full reports for further review and contacted nine authors for additional data. We excluded three studies that presented the same participants as previous reports, 18 -20 three studies that did not provide information to calculate prognostic accuracy, 21-23 two studies that adopted nondedicated PET scanner, 24, 25 one study with fewer than 10 relevant participants, 26 one study with fewer than five patients who progressed or relapsed, 27 and one study that evaluated patients during salvage therapy. 28 One study 29 presented updated results combining previous reports from two independent groups 13, 30 together with 106 newly evaluated patients from both groups. In this report, we included only the added subpopulation as an independent study. Three studies reported FDG-PET results at completion of second cycle and fourth cycle of chemotherapy. 13, 14, 31 We abstracted data only on the second cycle in these studies. One study evaluated ¶Patients underwent PET at the midpoint of the whole chemotherapy cycles (the end of the second cycle for 4-cycle chemotherapy regimens, the third cycle for 6-cycle regimens, and the fourth cycle for 8-cycle regimens).
#Only patients not included in the previous reports 13, 30 were left. ‫ءء‬Only patients in long-term remission.
† †For bi-weekly cycle chemotherapy [eg, (R-)ACVBP]. ‡ ‡Eleven patients underwent PET at the end of the fourth cycle. § §Eleven patients underwent PET at the end of the fourth cycle. §Abstracted from total participants of original report, not exclusively for relevant patient population. Some underwent high-dose chemotherapy followed by autologous stem-cell transplantation as consolidation therapy. ¶All received an eight-cycle biweekly consolidation therapy consisting high-dose methotrexate, etoposide, ifosfamide, and cytarabine after the ACVBP regimen. #All underwent high-dose chemotherapy followed by autologous stem-cell transplantation with or without rituximab maintenance therapy. ‫ءء‬ A portion of patients (n ϭ 16) with limited-stage disease underwent 2 to 4 cycles of (R-)CHOP followed by involved field radiation therapy instead of full course (R-)CHOP.
† †Patents with one age-adjusted international prognostic risk factor received an eight-cycle consolidation therapy, and patients with two or three factors underwent high-dose chemotherapy followed by autologous stem-cell transplantation.
‡ ‡All underwent high-dose chemotherapy followed by autologous stem-cell transplantation. § §A portion of patients (n ϭ 13) with limited-stage disease underwent 2 to 4 cycles of (R-)CHOP or similar regimens followed by involved field radiation therapy instead of full-cycle chemotherapy.
PET at varied timing ranging from the first to fifth cycle. 36 We contacted the investigators for individual patient data, and excluded one patient who underwent PET at the fifth cycle. We found one study 14 through hand searching of the reference lists. As a result, we included 13 studies: eight studies 13, 14, 29, 30, [32] [33] [34] [35] that met all eligibility criteria and five studies 12, 31, [36] [37] [38] with unpublished data available through contacting the authors (Table 1) .
12-14,29-36,38
Study Characteristics
Thirteen included studies had 360 advanced-stage HL patients and 311 DLBCL patients (Table 1) . Eight reports were prospective single-or multi-institutional studies enrolling adults or adolescents. Only one study evaluated both adults and children. 34 Most of the patients in the HL studies underwent PET after receiving two cycles of first-line chemotherapy, while the number of cycles before the PET scan varied in DLBCL studies. In three DLBCL studies, 25% to 52% of included patients underwent PET after the fourth cycle. 34, 36, 38 One study evaluated PET after one cycle. 32 In general, participants underwent PET during the second week of intended chemotherapy cycle for biweekly chemotherapies (eg, doxorubicin, bleomycin, vinblastine, dacarbazine [ABVD] or (R-) doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone [ACVBP]) and during the third week for triweekly regimens (eg, (R-) cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP] ). Four studies performed CT for a portion of patients at the same timing as interim PET but they did not perform direct comparison between the two tests. 13, 30, 36, 38 For advanced-stage HL studies, fewer than 10% of included patients had unfavorable risk by standard prognostic tool (IPS Ͼ 3 points; Table 2 ). Progression or relapse rates were between 20% and 30% except for one study of 50%. 32 All studies adopted currently available standard first-line chemotherapy: six to eight cycles of ABVD or comparable regimens with or without radiotherapy. For DLBCL studies, the percentage of patients with unfavorable prognosis (highintermediate to high risk by IPI) ranged from 0% to 59%, with progression or relapse rates of 27% to 47%. Full course (R-) CHOP and (R-) ACVBP were the two most widely adopted regimens. Two studies employed abbreviated course of (R-) CHOP or comparable regimens followed by involved-field radiation for patients with limited-stage disease. 12, 36 No patients received rituximab in one study. 34 In four studies, some patients received consolidation auto-transplant after induction chemotherapy. 31, 34, 35, 38 Concerning imaging techniques and technologies, included studies generally followed guidelines by the Society of Nuclear Medicine (Table 3) . One study exclusively adopted combined PET/CT scanner. 38 In five studies, some patients underwent combined PET/CT while the others were evaluated with stand-alone dedicated PET scanner. 13, 29, 30, 32, 36 All but one study 34 adopted attenuation correction for image reconstruction.
In general, multiple experienced nuclear medicine physicians interpreted PET results with pretherapy baseline scan as reference. All studies adopted qualitative positive and negative diagnostic criteria with various definitions (online-only Appendix Table A3 ). Only two studies clearly reported the referential backgrounds to define positive lesion. Five studies defined MRU criterion, 12-14,29,37 which was eventually reported as negative in three studies. 13, 14, 29 No study reported between-observer variability.
Quality Assessment of Published Studies
Only two studies 13, 35 reported all items of the QUADAS tool (online-only Appendix Table A4 ). Reporting was especially limited in Abbreviations: CT, computed tomography; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin's lymphoma; NR, not reported; OSEM, ordered subsets expectation maximization; PET, positron emission tomography; RAMLA, row-action maximum likelihood algorithm; SUV, standard uptake value. ‫ء‬ Three hundred seventy MBq/70 kg at the centers that used a GE scanner, 259 MBq/70 kg at the centers that used a Philips scanner, and 2 MBq/body weight kg at the centers that used a C-PET scanner.
†Administred activity was reported as the amount per body weight MBq/kg; eg, 360 MBq was administered to a 60 kg patient for 6 MBq/kg). ‡Mean Ϯ standard deviation.
three retrospective studies. 14,36,37 Physicians' knowledge of interim PET results may affect their assessment of patients' response as well as their treatment decisions, introducing biases. 39 Only three prospective studies 13, 29, 35 explicitly adopted blinding of clinicians to interim PET results to deal with these biases. In three prospective studies, 14,30,31 although they did not explicitly report the use of blinding, interim PET was not utilized to alter the preplanned treatment strategies. In two retrospective studies, 32, 38 interim PET results had no effect on the treatment decisions. Because the assessment of treatment failure is not always objective, the absence of blinding can still potentially influence the way treating physicians judge the final clinical outcome in favor of interim PET, especially when the outcome is equivocal.
11,39 Although all the studies adopted the standard guidelines on response assessment 40, 41 as the reference standard, they did not specify minimum follow-up period or situations where pathological confirmation was required. Four studies 29,32,33,38 employed post-therapy or follow-up PET to complement post-therapy response assessment. Because posttherapy response assessment with PET is still imperfect, 9 the applied reference standard could overestimate prognostic accuracy.
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Sensitivity, Specificity, LRs, and Summary ROC Curves
For advanced-stage HL, studies reported sensitivity from 0.67 to 1.00 and consistently high specificity from 0.94 to 1.00 for interim FDG-PET (Table 4; Fig 1) . Summary estimates were 0.81 for sensitivity (95% CI, 0.72 to 0.89), 0.97 for specificity (95% CI, 0.94 to 0.99), 28.4 for positive LR (95% CI, 14.2 to 56.7), and 0.19 for negative LR (95% CI, 0.12 to 0.30). We did not estimate summary ROC curves because data points were closely clustered together with limited variations, a situation in which the hierarchical model could not produce reliable estimates (Fig 2) .
DLBCL studies reported wide-ranging sensitivity (0.50 to 1.0) and specificity (0.73 to 1.00) values for interim FDG-PET (Table 4 ; Fig  1) . Combined estimates had a sensitivity of 0.78 (95% CI, 0.64 to 0.87), a specificity of 0.87 (95% CI, 0.75 to 0.93), a positive LR of 5.9 (95% CI, 2.8 to 12.3), and a negative LR of 0.26 (95% CI, 0.15 to 0.46). The Q* statistic for the summary ROC curve was 0.82 (Fig 2) .
In sensitivity analyses, the summary prognostic accuracy was stable for both advanced-stage HL and DLBCL regardless of how MRU results or early-censored cases without treatment failure were counted (results not shown). Regarding alternative reference standards based on the duration of clinical follow-up, subgroup data were available for five advanced-stage HL studies (n ϭ 232) 13, 14, 30, 32, 37 and five DLBCL studies (n ϭ 181) 12, 32, 35, 36, 38 (online-only Appendix Table A5). All DLBCL studies had improvement in sensitivity with loss of specificity when only progression during first-line therapy was counted by the alternative reference standard. A similar tendency was Fig A2) .
Subgroup Analyses and Meta-Regression Analyses
We did not perform subgroup analyses for advanced-stage HL because there were too few data points and there was little variation of the results across studies (Fig 1) . Visual assessment of the ROC plots of DLBCL studies did not identify meaningful subgroups (data not shown). Meta-regression analyses on both advanced-stage HL and DLBCL did not find any clinical or test characteristics to explain the observed variability (data not shown).
DISCUSSION
This systematic review of interim response assessment of FDG-PET for patients with untreated advanced-stage HL showed that studies consistently reported high specificity and positive LRs. Although study quality was limited in some studies, as demographic and clinical characteristics of included patients were reasonably comparable over the studies, our results should generally be applicable to adult and adolescent patients with low-to intermediate-risk (IPS 0 to 3) receiving standard full course ABVD or comparable regimens. Because the summary positive LR is very high, positive PET results after a few cycles of chemotherapy would probably have an excellent ability to predict poor responders. Patients with negative PET, which predicts good response during the therapy, still have a moderate risk of post-treatment relapse since the summary negative LR is 0.19.
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The reported sensitivity and specificity of DLBCL studies of interim FDG-PET varied. This review also identified considerable clinical heterogeneity in these studies. For example, studies included patients with varied risk of treatment failure and adopted various therapeutic interventions. Also, studies were heterogeneous in how PET was used, such as the number of chemotherapy cycles before PET and the timing of scanning during the chemotherapy cycle. 43 Thus, our summary estimates should be interpreted carefully. Although we performed subgroup analyses and meta-regression analyses, we could not identify characteristics to explain the variability.
This study has several important limitations. Because only 13 studies with pertinent data were included in the meta-analysis, it may lack the power to detect clinically meaningful factors. In sensitivity analyses, fewer studies were available; therefore, the results may be less reliable. Although we did not independently estimate the summary LR for a MRU result, this distinct category may carry a worse prognosis than a clearly negative scan as reported.
12,14 Also, our results are likely subject to overestimation due to methodologic limitations in original studies, such as the absence of blinding of interim PET results to clinicians to assess final clinical outcomes.
11 Further, because of lack of data, we did not address the comparison between FDG-PET and CT or FDG-PET/CT and PET alone 38 ; this review cannot answer whether PET is better than CT or whether the combined modality is superior to stand alone PET. In addition, this review did not specifically focus on limited-stage lymphoma; thus our results cannot answer the clinical question of whether early-interim PET can reliably identify good responders with localized disease. Finally, although three advanced-stage HL studies 13, 29, 30 and one DLBCL study 31 reported interim FDG-PET scan as a statistically significant independent prognostic factor in addition to IPS and IPI, respectively, we did not directly address this issue. For advanced-stage HL, because the included studies had few poor-risk (IPS 4 to 7) patients, our results may be less applicable to high-risk populations.
Interim PET should remain at this time as a test to be evaluated as part of clinical research where treatment regimens and imaging conditions are standardized; thus it should not be employed in the routine setting. This review supports conducting prospective trials for advanced-stage HL patients especially with low-to intermediate-risk (IPS 0 to 3) that incorporate early altering treatment to more intensive approach on the basis of positive FDG-PET results. For DLBCL, there is insufficient data to support similar trials. Additional prospective prognostic accuracy studies in the setting of conventional strategy would be needed to elucidate subgroups and timings of interim PET to better identify poor responders. Also, outside of study protocols where treatment strategies are explicitly defined on the basis of scan results, biopsy should be considered for positive PET findings if they are used to prompt a change in patient management. This is especially relevant if there is discrepancy between the scan results and other clinical data. Although biopsy cannot provide quantitative information as to how much residual tumor exists, it still is the most reliable way to confirm the presence of disease. 
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